Results of Rotavirus Vaccine Impact Analysis
Rotavirus vaccination in Palestine has significantly reduced the burden of diarrhea among children, and the benefits were sustained through a vaccine product switch. PATH, RVF and the Palestinian MOH have worked together to demonstrate the significant health impact of the rotavirus vaccine – first with ROTARIX, and then after switching to ROTAVAC. The results of this impact analysis confirm the significant benefit that the rotavirus immunization program has had on reducing the disease burden caused by rotavirus in Palestine. The findings also indicate that these benefits have been sustained through the transition from ROTARIX to ROTAVAC, providing reassurance of similar performance and safety across the two products. (Manuscript is in development for submission to a peer-reviewed journal.)
The full brief is available here.